Development of a group A meningococcal conjugate vaccine,MenAfriVacTM
- 12 June 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Human Vaccines & Immunotherapeutics
- Vol. 8 (6), 715-724
- https://doi.org/10.4161/hv.19619
Abstract
Group A meningococcal disease has been an important public health problem in sub-Saharan Africa for over a century. Outbreaks occur there annually, and large epidemics occur at intervals ranging between 8 and 12 y. The Meningitis Vaccine Project was established in 2001 with funding from the Gates Foundation with the goal of developing, testing, licensing, and introducing an affordable group A meningococcal conjugate vaccine into Africa. From 2003 to 2009 a monovalent group A conjugate vaccine, MenAfriVac(TM) , was developed at the Serum Institute of India, Ltd through an innovative public/private partnership. Preclinical studies of the new conjugate vaccine were completed in 2004 and a Phase 1 study began in India in 2005. Phase 2/3 studies in African 1-29 y olds were completed in 2009 showing the new meningococcal A conjugate vaccine to be as safe as currently licensed meningococcal polysaccharide vaccines, but much more immunogenic. After Indian market authorization (December 2009) and WHO prequalification (June 2010), MenAfriVac(TM) was introduced at public health scale using a single 10 µg dose in individuals 1-29 y of age in Burkina Faso, Mali, and Niger in December 2010. We summarize the laboratory and clinical studies leading to prequalification of MenAfriVac(TM). The 2011 epidemic season ended with no reported case of group A meningitis in vaccinated individuals.Keywords
This publication has 27 references indexed in Scilit:
- Baseline Meningococcal Carriage in Burkina Faso before the Introduction of a Meningococcal Serogroup A Conjugate VaccineClinical and Vaccine Immunology, 2011
- The epidemiology of meningococcal disease in IndiaTropical Medicine & International Health, 2010
- Bactericidal antibody is the immunologic surrogate of protection against meningococcal diseaseVaccine, 2009
- Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solutionVaccine, 2009
- Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in NigerClinical Infectious Diseases, 2007
- The Rise and Fall of EpidemicNeisseria meningitidisSerogroup W135 Meningitis in Burkina Faso, 2002–2005Clinical Infectious Diseases, 2006
- THE RELATIONSHIP BETWEEN GROUP A AND GROUP C MENINGOCOCCAL POLYSACCHARIDES AND SERUM OPSONINS IN MANThe Journal of Experimental Medicine, 1970
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969
- THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITISThe Journal of Experimental Medicine, 1913